G1 Therapeutics, Inc. GTHX
Set alert
7.16 0.00 0.00%
As of Sep 17, 3:56 PM ET
7.14 Day range 7.16
52-week range unavailable
- Open
- 7.15
- Prev close
- 7.16
- Mkt cap
- 377.75M
- Vol
- 1.10M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.14
- High
- 7.16
- Forward P/E
- 0.00
- Beta
- 1.68
- Short ratio
- 1.01
- Inst. own
- 54.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 6, 2024
- 50-d avg
- 5.84
- 200-d avg
- 4.10
- 1y target
- 7.15
Analyst view
Consensus: hold
Hold
Price target (mean) 7.15
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 6
- 2 months ago 6
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.09 | -0.13 – -0.06 | -0.35 | +74.3% | 18.80M | +52.8% | 2 |
| Next quarter | -0.06 | -0.11 – -0.01 | -0.21 | +71.4% | 20.83M | +40.1% | 2 |
| Current year | -0.48 | -0.59 – -0.37 | -0.93 | +48.4% | 71.61M | -13.2% | 2 |
| Next year | 0.00 | -0.03 – 0.03 | -0.48 | +100.0% | 92.66M | +29.4% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 2023 | JP Morgan | Downgrade | Neutral | Underweight |
| Aug 2, 2023 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 2, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 1, 2023 | EF Hutton | Reiterated | — | Buy |
| Aug 1, 2023 | Needham | Maintained | Buy | Buy |
| Jun 25, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 4, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 4, 2023 | Needham | Reiterated | Buy | Buy |
| May 3, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| May 3, 2023 | Raymond James | Maintained | — | Outperform |
| Apr 18, 2023 | Needham | Reiterated | — | Buy |
| Mar 1, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Feb 13, 2023 | Needham | Maintained | — | Buy |
| Feb 13, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Feb 12, 2023 | EF Hutton | Maintained | — | Buy |
| Jan 29, 2023 | JP Morgan | Upgrade | Underweight | Neutral |
| Jan 4, 2023 | EF Hutton | Initiated | — | Buy |
| Jan 2, 2023 | Needham | Maintained | — | Buy |
| Nov 1, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 15, 2022 | Wedbush | Maintained | — | Outperform |
| Aug 3, 2022 | Needham | Maintained | — | Buy |
| May 4, 2022 | Needham | Maintained | — | Buy |
| Nov 3, 2021 | JP Morgan | Downgrade | Neutral | Underweight |
| Nov 3, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 3, 2021 | Raymond James | Maintained | — | Outperform |
| Sep 29, 2021 | JP Morgan | Downgrade | Overweight | Neutral |
| Aug 31, 2021 | Roth Capital | Maintained | — | Buy |
| Feb 24, 2021 | Needham | Maintained | — | Buy |
| Aug 5, 2020 | Wedbush | Maintained | — | Outperform |
| May 11, 2020 | JP Morgan | Maintained | — | Overweight |